features: Ovarian Cancer
First-line maintenance with olaparib monotherapy and in combination bevacizumab increases survival in advanced ovarian cancer
Over 75% of patients with ovarian cancer are diagnosed at an advanced stage, as early-stage disease is usually asymptomatic.1,2 The…
Sig3 mutation and immune score determine responses to combination PARP and PD-1 inhibition in ovarian cancer
Immune checkpoint inhibitors have shown promising therapeutic outcomes in many types of cancer, but ovarian cancer has been an exception….